NO20064309L - Azabicyklo(3.1.0)heksanderivater anvendelige som modulatorer for dopamin D3 receptorer - Google Patents

Azabicyklo(3.1.0)heksanderivater anvendelige som modulatorer for dopamin D3 receptorer

Info

Publication number: NO20064309L
Authority: NO; Norway
Prior art keywords: group; 4alkyl; alkyl; cyano; halogen
Prior art date: 2004-02-23

Application number

NO20064309A

Other languages

English (en)

Norwegian (no)

Inventor

Romano Di Fabio

Luca Arista

Luca Tarsi

Silvia Terreni

Anna Maria Capelli

Gabriella Gentile

Fabrizio Micheli

Dieter Hamprecht

Giorgio Bonanomi

Federica Damiani

Giovanna Tedesco

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-23

Filing date

2006-09-22

Publication date

2006-11-23

2004-02-23 Priority claimed from GB0403990A external-priority patent/GB0403990D0/en

2004-02-24 Priority claimed from GB0404083A external-priority patent/GB0404083D0/en

2004-07-30 Priority claimed from GB0417120A external-priority patent/GB0417120D0/en

2006-09-22 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2006-11-23 Publication of NO20064309L publication Critical patent/NO20064309L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Nutrition Science (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO20064309A 2004-02-23 2006-09-22 Azabicyklo(3.1.0)heksanderivater anvendelige som modulatorer for dopamin D3 receptorer NO20064309L (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0403990A GB0403990D0 (en)	2004-02-23	2004-02-23	Compounds
GB0404083A GB0404083D0 (en)	2004-02-24	2004-02-24	Compounds
GB0417120A GB0417120D0 (en)	2004-07-30	2004-07-30	Compounds
PCT/EP2005/001940 WO2005080382A1 (en)	2004-02-23	2005-02-21	Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors

Publications (1)

Publication Number	Publication Date
NO20064309L true NO20064309L (no)	2006-11-23

Family

ID=34890800

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20064309A NO20064309L (no)	2004-02-23	2006-09-22	Azabicyklo(3.1.0)heksanderivater anvendelige som modulatorer for dopamin D3 receptorer

Country Status (25)

Country	Link
US (3)	US7855298B2 (da)
EP (3)	EP2060570B1 (da)
JP (1)	JP4960217B2 (da)
KR (1)	KR101143718B1 (da)
CN (1)	CN1946714B (da)
AR (1)	AR047890A1 (da)
AT (3)	ATE520686T1 (da)
AU (2)	AU2005215918C1 (da)
BR (1)	BRPI0507945A (da)
CA (1)	CA2557115C (da)
CY (3)	CY1109854T1 (da)
DE (1)	DE602005018190D1 (da)
DK (3)	DK1745040T3 (da)
ES (2)	ES2380990T3 (da)
HR (3)	HRP20100114T1 (da)
IL (1)	IL177184A0 (da)
MA (1)	MA28438B1 (da)
NO (1)	NO20064309L (da)
PE (1)	PE20051173A1 (da)
PL (3)	PL2070922T3 (da)
PT (3)	PT1745040E (da)
RU (1)	RU2434011C2 (da)
SI (3)	SI1745040T1 (da)
TW (1)	TW200538113A (da)
WO (1)	WO2005080382A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7855298B2 (en) *	2004-02-23	2010-12-21	Glaxo Group Limited	Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine D3 receptors
US20070043100A1 (en)	2005-08-16	2007-02-22	Hagen Eric J	Novel polymorphs of azabicyclohexane
GB0507601D0 (en) *	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507602D0 (en)	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507680D0 (en) *	2005-04-15	2005-05-25	Glaxo Group Ltd	Compounds
GB0512099D0 (en)	2005-06-14	2005-07-20	Glaxo Group Ltd	Compounds
EP1891056B1 (en)	2005-06-14	2010-10-13	Glaxo Group Limited	Novel compounds
WO2007006117A1 (en) *	2005-07-13	2007-01-18	Nicogen Inc.	Novel cyp2a6 inhibitors
EP1915146A4 (en)	2005-07-27	2010-06-02	Dov Pharmaceutical Inc	NOVEL 1-ARYL-3-AZABICYCLO [3.1.0] HEXANEES. PREPARATION AND USE FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES
GB0517191D0 (en)	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0517187D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
EP1919908B1 (en) *	2005-08-22	2010-11-10	Glaxo Group Limited	Triazole derivatives as modulators of dopamine d3 receptors
GB0517193D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Novel use
GB0517175D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
BRPI0709660A2 (pt)	2006-04-03	2011-07-19	Glaxo Group Limided	derivados de azabiciclo [3,1,0] hexila como moduladores dos receptores de dopamina d3
JP5189076B2 (ja) *	2006-04-03	2013-04-24	グラクソグループリミテッド	ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキシル誘導体
GB0607899D0 (en) *	2006-04-03	2006-05-31	Glaxo Group Ltd	Process for preparing heterocyclic derivatives
GB0703387D0 (en) *	2007-02-21	2007-03-28	Glaxo Group Ltd	Novel compounds
DE602007012531D1 (de) *	2006-04-03	2011-03-31	Glaxo Group Ltd	Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren
GB0608452D0 (en) *	2006-04-27	2006-06-07	Glaxo Group Ltd	Novel compounds
US20080045725A1 (en)	2006-04-28	2008-02-21	Murry Jerry A	Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
GB0616574D0 (en) *	2006-08-21	2006-09-27	Glaxo Group Ltd	Compounds
US8138377B2 (en)	2006-11-07	2012-03-20	Dov Pharmaceutical, Inc.	Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US20090069374A1 (en) *	2007-06-06	2009-03-12	Phil Skolnick	Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
US9133159B2 (en)	2007-06-06	2015-09-15	Neurovance, Inc.	1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
GB0719235D0 (en) *	2007-10-02	2007-11-14	Glaxo Group Ltd	Novel compounds
GB0719234D0 (en) *	2007-10-02	2007-11-14	Glaxo Group Ltd	Novel compounds
JP2011525533A (ja)	2008-06-24	2011-09-22	コデクシス，インコーポレイテッド	実質的に立体異性的に純粋な縮合二環式プロリン化合物の調製のための生体触媒法
US8536185B2 (en) *	2008-09-22	2013-09-17	Cayman Chemical Company, Incorporated	Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
US8906913B2 (en) *	2009-06-26	2014-12-09	Panacea Biotec Limited	Azabicyclohexanes
US20140206740A1 (en)	2011-07-30	2014-07-24	Neurovance, Inc.	Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
EP3068226A4 (en) *	2013-11-11	2017-05-17	Euthymics Bioscience, Inc.	Novel methods
AU2016303558B2 (en) *	2015-08-05	2020-08-06	Indivior Uk Limited	Dopamine D3 receptor antagonists having a bicyclo moiety
WO2019146740A1 (ja)	2018-01-26	2019-08-01	塩野義製薬株式会社	ドーパミンｄ３受容体拮抗作用を有する環式化合物
KR20230027245A (ko)	2020-06-22	2023-02-27	코어셉트 쎄라퓨틱스 인코포레이티드	4차 인다졸 글루코코르티코이드 수용체 길항제
US12115154B2 (en)	2020-12-16	2024-10-15	Srx Cardio, Llc	Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
AU2022417485A1 (en)	2021-12-21	2024-07-04	Corcept Therapeutics Incorporated	Piperazine indazole glucocorticoid receptor antagonists
CA3243547A1 (en)	2021-12-21	2023-06-29	Corcept Therapeutics Inc	INDAZOLE GLUCOCORTICOID RECEPTOR BICYCLIC ANTAGONISTS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR022230A1 (es) *	1999-01-12	2002-09-04	Abbott Gmbh & Co Kg	Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
GB0015562D0 (en) *	2000-06-23	2000-08-16	Pfizer Ltd	Heterocycles
BR0115328A (pt)	2000-11-14	2004-04-06	Smithkline Beecham Plc	Derivados de tetraidro benzazepina úteis como moduladores dos receptores d3 de dopamina (agentes anti-psicóticos
US6569887B2 (en) *	2001-08-24	2003-05-27	Dov Pharmaceuticals Inc.	(−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
AP1816A (en) *	2001-10-22	2008-01-04	Pfizer Prod Inc	3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists.
CN1894241A (zh) *	2002-08-09	2007-01-10	阿斯利康(瑞典)有限公司	作为代谢型谷氨酸受体－5调节剂的“1,2,4” 噁二唑
US7855298B2 (en) *	2004-02-23	2010-12-21	Glaxo Group Limited	Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine D3 receptors
GB0507602D0 (en)	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507601D0 (en) *	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507680D0 (en) *	2005-04-15	2005-05-25	Glaxo Group Ltd	Compounds
EP1891056B1 (en)	2005-06-14	2010-10-13	Glaxo Group Limited	Novel compounds
GB0517193D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Novel use
EP1919908B1 (en) *	2005-08-22	2010-11-10	Glaxo Group Limited	Triazole derivatives as modulators of dopamine d3 receptors
GB0517191D0 (en)	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0517175D0 (en)	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0517187D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
BRPI0709660A2 (pt)	2006-04-03	2011-07-19	Glaxo Group Limided	derivados de azabiciclo [3,1,0] hexila como moduladores dos receptores de dopamina d3
GB0616574D0 (en) *	2006-08-21	2006-09-27	Glaxo Group Ltd	Compounds

2005
- 2005-02-21 US US10/598,200 patent/US7855298B2/en not_active Expired - Fee Related
- 2005-02-21 SI SI200530923T patent/SI1745040T1/sl unknown
- 2005-02-21 HR HR20100114T patent/HRP20100114T1/hr unknown
- 2005-02-21 PT PT05707610T patent/PT1745040E/pt unknown
- 2005-02-21 PL PL08169934T patent/PL2070922T3/pl unknown
- 2005-02-21 EP EP08169935A patent/EP2060570B1/en not_active Expired - Lifetime
- 2005-02-21 AT AT08169934T patent/ATE520686T1/de active
- 2005-02-21 AT AT08169935T patent/ATE542816T1/de active
- 2005-02-21 PL PL05707610T patent/PL1745040T3/pl unknown
- 2005-02-21 EP EP05707610A patent/EP1745040B9/en not_active Expired - Lifetime
- 2005-02-21 RU RU2006133909/04A patent/RU2434011C2/ru not_active IP Right Cessation
- 2005-02-21 KR KR1020067016833A patent/KR101143718B1/ko not_active Expired - Fee Related
- 2005-02-21 TW TW094105108A patent/TW200538113A/zh unknown
- 2005-02-21 SI SI200531398T patent/SI2070922T1/sl unknown
- 2005-02-21 PT PT08169935T patent/PT2060570E/pt unknown
- 2005-02-21 DK DK05707610.1T patent/DK1745040T3/da active
- 2005-02-21 SI SI200531503T patent/SI2060570T1/sl unknown
- 2005-02-21 CN CN2005800126155A patent/CN1946714B/zh not_active Expired - Fee Related
- 2005-02-21 CA CA2557115A patent/CA2557115C/en not_active Expired - Fee Related
- 2005-02-21 DE DE602005018190T patent/DE602005018190D1/de not_active Expired - Lifetime
- 2005-02-21 DK DK08169934.0T patent/DK2070922T3/da active
- 2005-02-21 WO PCT/EP2005/001940 patent/WO2005080382A1/en not_active Ceased
- 2005-02-21 AT AT05707610T patent/ATE451364T1/de active
- 2005-02-21 JP JP2007500152A patent/JP4960217B2/ja not_active Expired - Fee Related
- 2005-02-21 ES ES08169935T patent/ES2380990T3/es not_active Expired - Lifetime
- 2005-02-21 AU AU2005215918A patent/AU2005215918C1/en not_active Ceased
- 2005-02-21 AR ARP050100632A patent/AR047890A1/es not_active Application Discontinuation
- 2005-02-21 PE PE2005000205A patent/PE20051173A1/es not_active Application Discontinuation
- 2005-02-21 PT PT08169934T patent/PT2070922E/pt unknown
- 2005-02-21 DK DK08169935.7T patent/DK2060570T3/da active
- 2005-02-21 EP EP08169934A patent/EP2070922B1/en not_active Expired - Lifetime
- 2005-02-21 BR BRPI0507945-4A patent/BRPI0507945A/pt active Search and Examination
- 2005-02-21 PL PL08169935T patent/PL2060570T3/pl unknown
- 2005-02-21 ES ES05707610T patent/ES2337590T3/es not_active Expired - Lifetime
2006
- 2006-07-31 IL IL177184A patent/IL177184A0/en unknown
- 2006-08-22 MA MA29286A patent/MA28438B1/fr unknown
- 2006-09-22 NO NO20064309A patent/NO20064309L/no not_active Application Discontinuation
2009
- 2009-09-01 AU AU2009212887A patent/AU2009212887A1/en not_active Abandoned
- 2009-12-16 US US12/639,129 patent/US8263782B2/en not_active Expired - Fee Related
- 2009-12-16 US US12/639,282 patent/US8283474B2/en not_active Expired - Fee Related
2010
- 2010-03-01 CY CY20101100197T patent/CY1109854T1/el unknown
2011
- 2011-10-26 HR HR20110781T patent/HRP20110781T1/hr unknown
- 2011-11-07 CY CY20111101073T patent/CY1112011T1/el unknown
2012
- 2012-03-29 HR HR20120281T patent/HRP20120281T1/hr unknown
- 2012-04-11 CY CY20121100356T patent/CY1113029T1/el unknown

Also Published As

Publication number	Publication date
DK2060570T3 (da)	2012-04-30
HRP20100114T1 (hr)	2010-04-30
IL177184A0 (en)	2006-12-10
JP2007523208A (ja)	2007-08-16
TW200538113A (en)	2005-12-01
KR101143718B1 (ko)	2012-07-05
PT2060570E (pt)	2012-05-07
ES2337590T3 (es)	2010-04-27
KR20060127991A (ko)	2006-12-13
PL1745040T3 (pl)	2010-05-31
BRPI0507945A (pt)	2007-07-24
DK2070922T3 (da)	2011-11-28
EP2060570A3 (en)	2009-06-03
PT1745040E (pt)	2010-03-08
PL2070922T3 (pl)	2012-01-31
SI2060570T1 (sl)	2012-05-31
SI2070922T1 (sl)	2011-12-30
ATE451364T1 (de)	2009-12-15
CY1112011T1 (el)	2015-11-04
ATE542816T1 (de)	2012-02-15
HRP20120281T1 (hr)	2012-04-30
EP2060570A2 (en)	2009-05-20
CY1113029T1 (el)	2016-04-13
EP2060570B1 (en)	2012-01-25
AU2005215918C1 (en)	2010-01-21
HRP20110781T1 (hr)	2011-11-30
EP2070922A1 (en)	2009-06-17
EP1745040B9 (en)	2010-06-02
CN1946714A (zh)	2007-04-11
DK1745040T3 (da)	2010-04-12
DE602005018190D1 (de)	2010-01-21
PT2070922E (pt)	2011-11-24
MA28438B1 (fr)	2007-02-01
US20100160336A1 (en)	2010-06-24
CA2557115C (en)	2012-10-02
ATE520686T1 (de)	2011-09-15
HK1103016A1 (en)	2007-12-14
US8283474B2 (en)	2012-10-09
EP1745040A1 (en)	2007-01-24
EP2070922B1 (en)	2011-08-17
US8263782B2 (en)	2012-09-11
SI1745040T1 (sl)	2010-04-30
CY1109854T1 (el)	2014-09-10
RU2434011C2 (ru)	2011-11-20
AU2005215918B2 (en)	2009-06-11
WO2005080382A1 (en)	2005-09-01
AU2009212887A1 (en)	2009-09-24
CA2557115A1 (en)	2005-09-01
AU2005215918A1 (en)	2005-09-01
JP4960217B2 (ja)	2012-06-27
US7855298B2 (en)	2010-12-21
PL2060570T3 (pl)	2012-06-29
PE20051173A1 (es)	2006-02-14
AR047890A1 (es)	2006-03-01
EP1745040B1 (en)	2009-12-09
RU2006133909A (ru)	2008-03-27
US20100152195A1 (en)	2010-06-17
US20070142438A1 (en)	2007-06-21
ES2380990T3 (es)	2012-05-22
CN1946714B (zh)	2011-06-15

Publication	Publication Date	Title
NO20064309L (no)	2006-11-23	Azabicyklo(3.1.0)heksanderivater anvendelige som modulatorer for dopamin D3 receptorer
DE602006018152D1 (de)	2010-12-23	Triazolderivate als modulatoren von dopamin-d3-rezeptoren
CO6251248A2 (es)	2011-02-21	Compuestos de tiazolopiridina como moduladores de sirtuina
AR085615A1 (es)	2013-10-16	Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
NO20092770L (no)	2009-09-25	Nye aminopyrimidinderivater som PLK1-inhibitorer
AR060237A1 (es)	2008-06-04	Compuesto de 3-azabiciclo[3.1.0]hexano como moduladores del receptor de dopamina d3, su uso para la preparacion de un medicamento para el tratamiento de afecciones psicoticas y composicion farmaceutica que lo comprende.
TW200604186A (en)	2006-02-01	Compounds
MX2009004780A (es)	2009-05-21	Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico.
MY152805A (en)	2014-11-28	Benzazepine derivatives useful as vasopressin antagonists
DE602006006850D1 (de)	2009-06-25	Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
AR067412A1 (es)	2009-10-07	Moduladores de propiedades farmaceuticas de productos terapeuticos
ATE493404T1 (de)	2011-01-15	Azabicyclo-(3,1,0)-hexan-derivate als modulatoren von dopamin-d3-rezeptoren
AR077367A1 (es)	2011-08-24	2- carboxamida -cicloamino-ureas sustituidas
MY153042A (en)	2014-12-31	Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
CY1112679T1 (el)	2016-02-10	Κινολινες και θεραπευτικη χρηση αυτων
NO20063355L (no)	2006-09-22	Nye trisykliske spiroderivater som modulatorer for kemokinreseptoraktivitet
ATE512142T1 (de)	2011-06-15	Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität
DE602006011725D1 (de)	2010-03-04	3-triazolylthioalkyl-3-azabicyclo ä3.1.0ühexane und ihre verwendung als liganden des dopamin-d3-rezeptors
DE602006017543D1 (de)	2010-11-25	Neue verbindungen
MX2012008147A (es)	2012-08-03	Derivados de pirrazolopiridina.
PE20070212A1 (es)	2007-03-21	Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
IN2012DN02871A (da)	2015-07-24
ATE539053T1 (de)	2012-01-15	Azabicyclo ä3. 1. 0ü-hexylderivate als modulatoren von dopamin-d3-rezeptoren
ATE452636T1 (de)	2010-01-15	3-azabicycloä4.1.0üheptan-derivate zur behandlung von depressionen
NO20084415L (no)	2008-12-08	Azabicyklo[3.1.0]heksylderivater som modulatorer av dopamin D3 receptorer

Legal Events

Date	Code	Title	Description
2013-05-21	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: GLAXO GROUP LTD, GB
2016-02-29	FC2A	Withdrawal, rejection or dismissal of laid open patent application